Results 141 to 150 of about 23,157 (220)

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV in Asia: 24-Month findings from the observational BICSTaR study. [PDF]

Medicine (Baltimore)
Yang CJ, Kim YS, Choi JY, Choy CY, Lu PL, Tsai HC, Ryu J, Harrison R, Chang J, Mo B, Lee SH, Hung CC.   +11 more
europepmc   +1 more source

Effectiveness and Safety Profile of BIC/TAF/FTC in People living with HIV Switched from Other Antiretroviral Regimens: A Real-Life Retrospective Cohort Analysis. [PDF]

Infez Med
Pipitone G, Marrali D, Goad M, Giordano M, Abbott M, Gizzi A, Sanfilippo A, Marascia FG, Agrenzano S, Imburgia C, Cascio A, Iaria C.   +11 more
europepmc   +1 more source

Balancing Act: Lessons From Comanaging Patients With Inflammatory Bowel Disease and HIV/AIDS. [PDF]

ACG Case Rep J
Cruz Grave E, Paik P, Kim J, Odufalu FD.
europepmc   +1 more source

Bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir plus lamivudine plus tenofovir disoproxil fumarate in people living with HIV experiencing virologic failure in China: a study protocol for a multicenter, open-label, randomized controlled non-inferiority trial. [PDF]

Trials
Wang R, Ren Y, Li R, Liu H, Liu X, Hua W, Wang X, Cao Y, Sun L, Dai L.   +9 more
europepmc   +1 more source

Commentary on PURPOSE-1 and PURPOSE-2 trials of lenacapavir: a breakthrough in HIV prevention. [PDF]

Ann Med Surg (Lond)
Idrees M, Iftikhar H, Sohail F, Jadoon M, Khan MH.   +4 more
europepmc   +1 more source